Form 4: Corvus Pharmaceuticals Director Linda Grais Acquires Stock Options
SEC Form 4 Filing
Director Linda Grais acquired 15,000 stock options in Corvus Pharmaceuticals on June 13, 2024.
Summary
- On June 13, 2024, Linda Grais, a director of Corvus Pharmaceuticals, acquired 15,000 stock options.
- The exercise price of these options is $2.12.
- The options vest on the earlier of June 13, 2025, or the date of the 2025 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director.
- The options expire on June 13, 2034.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a routine disclosure of stock option acquisition by a director.
Industry Context
This is a standard Form 4 filing, indicating a change in beneficial ownership by a company insider. Such filings are common and provide transparency into the trading activities of company directors and officers.
Stakeholder Impact
- The acquisition of stock options by a director can be seen as a positive sign by shareholders, as it aligns the director's interests with the company's long-term success.
Key Dates
| Date | Description |
|---|---|
| 06/13/2024 | Date of transaction: Linda Grais acquired 15,000 stock options. |
| 06/13/2025 | Earliest vesting date for the stock options, assuming continuous service as a director. |
| 06/13/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.